ライフサイエンスコーパス: ticlopidine

1 ine derivative, may be a safe alternative to ticlopidine.

2 clofenac, imipramine, meclofenamic acid, and ticlopidine.

3 r side effects make it a safe alternative to ticlopidine.

4 lopidogrel exhibits better tolerability than ticlopidine.

5 er clopidogrel is at least as efficacious as ticlopidine.

6 ng acetylsalicylic acid, clopidogrel, and/or ticlopidine.

7 utine antiplatelet therapy with aspirin plus ticlopidine.

8 All patients received aspirin and ticlopidine.

9 d chemical structure are similar to those of ticlopidine.

10 angiopathy, be aware of its association with ticlopidine.

11 ts who received either clopidogrel (2.1%) or ticlopidine (1.4%; p = 0.57) therapy.

12 patients randomized to placebo also received ticlopidine 250 mg orally BID for 4 weeks.

13 tive stent patients treated with aspirin and ticlopidine (500 mg loading dose and 250 mg twice daily

14 and warfarin (550 patients), or aspirin and ticlopidine (546 patients).

15 y (n = 26) were more likely to have received ticlopidine (92.3% vs. 46.2%, p < 0.003).

16 has been infrequently associated with use of ticlopidine, a platelet anti-aggregating agent.

17 emilofiban (5, 10, 15, or 20 mg) or placebo (ticlopidine) administered 8 to 18 hours after terminatio

18 360 patients who discontinued clopidogrel or ticlopidine after 6 months, stent thrombosis subsequentl

19 nd tolerability of clopidogrel compared with ticlopidine after coronary stent deployment.

20 common, and affected patients must switch to ticlopidine after drug-eluting stent placement, despite

21 All stented patients also received ticlopidine after the procedure, but 58% of these patien

22 alone, aspirin and warfarin, and aspirin and ticlopidine - after coronary stenting.

23 n, clopidogrel confers similar protection as ticlopidine against subacute stent thrombosis and major

24 Prophylaxis with antiplatelets (aspirin, ticlopidine [alone or in combination], eptifibatide, or

25 d by 133 (14.7%) of 902 patients assigned to ticlopidine and 112 (12.3%) of 907 patients assigned to

26 A total of 902 patients received 500 mg/d of ticlopidine and 907 received 650 mg/d of aspirin.

27 ients with stents were treated with aspirin, ticlopidine and a 60-h tapering heparin regimen.

28 went coronary stenting and were treated with ticlopidine and aspirin (TA group, n=1406), and patients

29 acy of clopidogrel and aspirin with those of ticlopidine and aspirin in patients undergoing coronary

30 statistically significant difference between ticlopidine and aspirin in the prevention of recurrent s

31 Dual antiplatelet therapy with ticlopidine and aspirin is routinely used with stenting,

32 Ticlopidine and clopidogrel achieve antiplatelet effects

33 f efficacious antithrombotic agents, such as ticlopidine and clopidogrel and AR-C66096.

34 Ticlopidine and clopidogrel seem to have beneficial effe

35 yridamole (Persantine), and thienopyridines (ticlopidine and clopidogrel) are all examples of agents

36 The thienopyridine derivatives, ticlopidine and clopidogrel, are a suitable alternative

37 The thienopyridine derivatives, ticlopidine and clopidogrel, are the 2 most common drugs

38 linical settings include the thienopyridines ticlopidine and clopidogrel, specific inhibitors of ADP-

39 o be the target of the thienopyridine drugs, ticlopidine and clopidogrel.

40 curred in 3.64% of the patients treated with ticlopidine and in 1.62% of the patients treated with cl

41 vent occurred in 4.60% of patients receiving ticlopidine and in 3.85% of patients receiving clopidogr

42 veloping thrombotic microangiopathy while on Ticlopidine and the possible mechanisms underlying this

43 scussed: mitomycin C, cyclosporine, quinine, ticlopidine, and clopidogrel.

44 Standard adjunctive therapy with aspirin, ticlopidine, and heparin was used.

45 The antiplatelet agents aspirin, ticlopidine, and the combination of dipyridamole and asp

46 ed antiplatelet drugs, including aspirin and ticlopidine, are effective against certain but not all o

47 2 antagonists (separate from clopidogrel and ticlopidine) as an approach to the treatment of thromboe

48 Aspirin plus ticlopidine, as well as abciximab, protected 45%-88% of

49 The onset of ticlopidine-associated thrombotic thrombocytopenic purpu

50 Instances of ticlopidine-associated thrombotic thrombocytopenic purpu

51 The estimated incidence of ticlopidine-associated thrombotic thrombocytopenic purpu

52 h clopidogrel-associated TTP cases (n = 35), ticlopidine-associated TTP cases (n = 93) were more like

53 In the patients who developed ticlopidine-associated TTP, autoantibodies to the vWF me

54 cedure, but 58% of these patients were given ticlopidine before stenting at the discretion of the inv

55 ng patients randomized to stenting, starting ticlopidine before the percutaneous coronary interventio

56 lyses revealed a less than 1% probability of ticlopidine being shown superior to aspirin in the preve

57 idogrel has a similar mechanism of action as ticlopidine, but both its efficacy and its safety as a p

58 1 in 1600 to 1 in 5000 patients who receive ticlopidine, but little is known about the pathogenesis

59 However, ticlopidine causes neutropenia in 1% of patients when ad

60 Y(12) is the target of antithrombotic drugs (ticlopidine, clopidogrel), whereas the role of P2Y(1) in

61 ine), and immune-mediated reaction (quinine, ticlopidine, clopidogrel).

62 rapy with aspirin and a P2Y12 inhibitor (eg, ticlopidine, clopidogrel, prasugrel, ticagrelor) reduces

63 tients with acute idiopathic, recurrent, and ticlopidine/clopidogrel-associated TTP.

64 With ticlopidine-containing regimens, the acute clinical resu

65 Ticlopidine could be modeled into the electron density m

66 teristics and for the propensity of being on ticlopidine, Cox proportional hazards regression identif

67 were closely monitored for side effects from ticlopidine developed side effects requiring its discont

68 Clopidogrel is better tolerated than ticlopidine during a 2-week regimen after intracoronary

69 Four patients (21%) received ticlopidine for 2 weeks or fewer, 14 patients (74%) for

70 hout thrombocytopenia who had been receiving ticlopidine for 3 to 5 weeks and 10 randomly selected ho

71 he animals received aspirin for 6 months and ticlopidine for 30 days.

72 were selected for a protocol of aspirin and ticlopidine (for 1 month) without anticoagulation.

73 smaller final lumen diameter and absence of ticlopidine from the poststent regimen.

74 ent occurred in 1.92% of the patients in the ticlopidine group and in 2.02% of the clopidogrel group

75 r in the clopidogrel group compared with the ticlopidine group-0.48% versus 1.09% (OR 0.55, 95% CI 0.

76 0% in the clopidogrel group and 4.04% in the ticlopidine group.

77 Data Synthesis: Ticlopidine had been prescribed for less than 1 month in

78 hrombosis did not occur in any patient after ticlopidine had been stopped.

79 Combined therapy with abciximab and ticlopidine has a prolonged inhibitory effect on mural t

80 Ticlopidine has been shown to reduce the incidence of st

81 Ticlopidine hydrochloride is 1 of several drugs that hav

82 ety and efficacy have not been compared with ticlopidine in a randomized manner in the United States.

83 Clopidogrel is similar to ticlopidine in chemical structure and function but has f

84 se effects, clopidogrel has largely replaced ticlopidine in clinical practice.

85 nd registries that compared clopidogrel with ticlopidine in patients receiving coronary stents were p

86 at clopidogrel can be safely substituted for ticlopidine in patients receiving coronary stents.

87 nt with the platelet ADP-receptor antagonist ticlopidine in preventing both the early and late compli

88 side effects, is at least as efficacious as ticlopidine in reducing MACE.

89 Stent thrombosis is reduced when ticlopidine is administered with aspirin.

90 in is routinely used with stenting, although ticlopidine is commonly not begun until the day of the p

91 n and either clopidogrel (n = 514; 58.7%) or ticlopidine (n = 361; 41.3%) therapy.

92 and little is known about the duration that ticlopidine needs be administered to prevent stent throm

93 84), and postoperative use of clopidogrel or ticlopidine (odds ratio, 1.35; 95% confidence interval,

94 received antiplatelet therapy (aspirin plus ticlopidine) only.

95 among patients receiving aspirin and either ticlopidine or clopidogrel during coronary stenting.

96 antiplatelet therapy with aspirin and either ticlopidine or clopidogrel for one month.

97 t and dual antiplatelet therapy (aspirin and ticlopidine or clopidogrel for two to four weeks).

98 If TTP occurs after 2 weeks of ticlopidine or clopidogrel therapy, therapeutic plasma e

99 tinuation of oral antiplatelet therapy (with ticlopidine or clopidogrel) and only in patients who had

100 ation were randomly assigned to therapy with ticlopidine or clopidogrel.

101 s were randomized to receive placebo (250 mg ticlopidine P.O. BID) or xemilofiban in doses of 5, 10,

102 significant reduction favoring aspirin over ticlopidine (P =.08 by log-rank test).

103 nd 30 (5.5 percent) who received aspirin and ticlopidine (P<0.001 for the comparison of all three gro

104 0.5 percent) assigned to receive aspirin and ticlopidine (P=0.001 for the comparison of all three gro

105 0.4% in clopidogrel patients versus 1.1% in ticlopidine patients; nonfatal myocardial infarction occ

106 ore, clopidogrel plus aspirin should replace ticlopidine plus aspirin as the standard antiplatelet re

107 Ticlopidine-plus-aspirin has become standard antiplatele

108 et inhibitors: thienopyridines (clopidogrel, ticlopidine, prasugrel) or IIb/IIIa receptor antagonists

109 x proportional hazards regression identified ticlopidine pretreatment as an independent predictor of

110 Ticlopidine pretreatment did not significantly influence

111 Ticlopidine pretreatment of > or =3 days was associated

112 Among patients randomized to placebo, ticlopidine pretreatment was associated with a significa

113 Longer duration of ticlopidine pretreatment was strongly associated with a

114 he adenosine diphosphate receptor antagonist ticlopidine prior to intracoronary stenting is associate

115 mes in 175 consecutive patients treated with ticlopidine prior to stenting at the Cleveland Clinic Fo

116 Abciximab and ticlopidine reduce adverse cardiovascular events after p

117 ing coronary artery stenting have shown that ticlopidine reduces the risk for subacute stent thrombos

118 timal" stenting combined with an aspirin and ticlopidine regimen carries a low (0.5%) incidence of su

119 rin and warfarin, treatment with aspirin and ticlopidine resulted in a lower rate of stent thrombosis

120 After coronary stenting, aspirin and ticlopidine should be considered for the prevention of t

121 the observed 30-day event rate of 1.6% with ticlopidine, the statistical power of the study was 43%

122 intracoronary stents, the discontinuation of ticlopidine therapy 14 days after stent placement is ass

123 lled: 522 patients were randomly assigned to ticlopidine therapy and 494 to clopidogrel.

124 Ten additional cases of TTP related to ticlopidine therapy following stenting were identified f

125 inical presentation and course of TTP due to ticlopidine therapy following stenting.

126 study was to determine if combined abciximab/ticlopidine therapy inhibits arterial thrombosis more ef

127 Ticlopidine therapy is an important risk factor for TTP.

128 ary stents, stent thrombosis is reduced when ticlopidine therapy is combined with aspirin after the p

129 eveloped thrombotic microangiopathy while on ticlopidine therapy is reported.

130 Of the 3 treatments, combined abciximab/ticlopidine therapy produced the most consistent reducti

131 undergoing intracoronary stenting, beginning ticlopidine therapy several days prior to the procedure

132 Limiting ticlopidine therapy to 2 weeks after stenting does not p

133 ergoing PTCA who received abciximab therapy, ticlopidine therapy, or both treatments were evaluated u

134 anied plasma exchange and discontinuation of ticlopidine therapy.

135 conformation allows smaller ligands such as ticlopidine to bind to the 2B6 active site in the expect

136 in one clopidogrel-treated (0.2%) and in one ticlopidine-treated (0.3%) patient (p = 0.99).

137 One ticlopidine-treated patient developed thrombocytopenia,

138 e similar among the clopidogrel- (99.6%) and ticlopidine-treated patients (99.4%).

139 of a TTP incidence of 0.02% in our cohort of ticlopidine-treated patients following coronary stenting

140 hrombosis for only 1 day after PTCA, whereas ticlopidine treatment alone had no significant effect.

141 Three days after PTCA, abciximab/ticlopidine treatment decreased mural thrombus formation

142 The mean time of ticlopidine treatment prior to TTP diagnosis was 22 days

143 d of continuous aspirin but relatively brief ticlopidine treatment.

144 Because of the association between ticlopidine use and thrombotic thrombocytopenic purpura

145 Ticlopidine use may be associated with the development o

146 eeks of ticlopidine were exclusion criteria; ticlopidine was discontinued after 14 days in all remain

147 Ticlopidine was first shown to decrease major events com

148 d NMR relaxation of drug protons showed that ticlopidine was preferentially oriented with the chlorop

149 failure) in the 15th through 30th days after ticlopidine was stopped.

150 mic event with clopidogrel, as compared with ticlopidine, was 0.72 (95% confidence interval [CI] 0.59

151 and the risk of serious adverse events with ticlopidine, we regard aspirin as a better treatment for

152 t in research protocols requiring 4 weeks of ticlopidine were exclusion criteria; ticlopidine was dis

153 ports of TTP associated with clopidogrel and ticlopidine were identified from medical records, publis

154 wed by antiplatelet therapy with aspirin and ticlopidine were pooled for this analysis.

155 with the antiplatelet drugs clopidogrel and ticlopidine, which were expected to have greater freedom

156 he study compared the safety and efficacy of ticlopidine with clopidogrel in patients receiving coron

157 ged safely with a combination of aspirin and ticlopidine without anticoagulation.